Amylyx Pharmaceuticals (AMLX) Earnings Call Presentation

Results from A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol (PB&TURSO) in Wolfram Syndrome (HELIOS) Lahar Mehta, MD Head of Global Clinical Development Amylyx Pharmaceuticals Additional Authors: Fumihiko Urano, MD, PhD; Stacy Hurst, RN, BSN, CDE; Bess Marshall, MD; Mathias Leinders, PhD; Nathalie Erpelding, PhD; Kelsi Cottrell; John Pesko, PhD 1 For scientific meeting use only. Do not duplicate, distribute, or disseminate. Copyright © 2024 Am ...